Ready to deliver relief3,4


Today, with Precision Olfactory Delivery (POD®) technology, patients can have the proven efficacy of dihydroergotamine mesylate (DHE) on demand for rapid, sustained, consistent relief, even when taken late into a migraine attack.2,4-7

Exploratory endpoints and post hoc analyses of patient-reported efficacy data for some patients showed the following results7*:

Rapid

Pain relief in as fast as 15 minutes6

Sustained

Pain freedom lasted 2 days with 1 dose8

Consistent

Delivered results time after time, even with difficult-to-treat migraine6

No dosing window

Relief on their terms, even when taken late into a migraine attack5-7

*Based on the phase 3, open-label safety study that enrolled 360 patients with migraine, which assessed safety, tolerability, and exploratory efficacy of Trudhesa™.7

Trudhesa Difference

References: 1. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006;46(suppl 4):S212-S220. 2. Trudhesa. Prescribing information. Impel Neuropharma; 2021. 3. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 4. Smith TR, Aurora S, Hocevar-Trnka J, Shrewsbury S. Acute treatment of migraine with INP104: exploratory efficacy from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 5. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020. 6. Data on File. Impel Neuropharma. 2020. 7. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients [published online ahead of print, 2021 Aug 7]. Headache. 2021;10.1111/head.14184. doi:10.1111/head.14184. 8. Tepper SJ, Ailani J, Shrewsbury SB, Aurora SK. Recurrence rates for INP104 for the acute treatment of migraine: results from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021.